The latest price target for Moderna (NASDAQ:MRNA) was reported by Argus Research on December 18, 2024. The analyst firm set a price target for $0.00 expecting MRNA to fall to within 12 months (a possible -100.00% downside). 55 analyst firms have reported ratings in the last year.

The latest analyst rating for Moderna (NASDAQ:MRNA) was provided by Argus Research, and Moderna downgraded their hold rating.

The last upgrade for Moderna Inc happened on November 18, 2024 when HSBC raised their price target to $58. HSBC previously had a hold for Moderna Inc.

The last downgrade for Moderna Inc happened on December 18, 2024 when Argus Research changed their price target from N/A to N/A for Moderna Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moderna, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moderna was filed on December 18, 2024 so you should expect the next rating to be made available sometime around December 18, 2025.

While ratings are subjective and will change, the latest Moderna (MRNA) rating was a downgraded with a price target of $0.00 to $0.00. The current price Moderna (MRNA) is trading at is $39.39, which is out of the analyst’s predicted range.